1. Scrip
  2. >>Business

US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce

AZ’s planned Alexion acquisition may be an early target

 
• By Sten Stovall

Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation. 

Competition Law
Aim is to identify ways to scrutinize Pharma deals more closely • Source: Shutterstock

AstraZeneca PLC’s proposed acquisition of Alexion could become the first test balloon for the newly announced international taskforce that anti-trust regulators in the US, Europe and the UK hope can curb M&A deals that threaten competition and restrict innovation in the medical field, analysts said.

Responding to the recent stream of pharmaceutical mergers, antitrust regulators and enforcement agencies from the US, Europe and the UK are forming a working group to better assess and understand...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.